List view / Grid view
Eli Lilly and Company
Filter the results
The UK's NICE has recommended Emgality (galcanezumab) for the prevention of migraine in adults with episodic and chronic migraine.
The neutralising antibody therapy bamlanivimab (LY-CoV555) is authorised for emergency use in recently diagnosed patients who are at risk of developing severe COVID-19.
Eli Lilly will provide the US government with vials of its COVID-19 antibody therapy bamlanivimab (LY-CoV555) if the treatment is granted Emergency Use Authorisation.
A study of baricitinib in combination with remdesivir has met its primary endpoint in COVID-19 patients, by reducing time to recovery in comparison with only remdesivir.
Two randomised Phase III clinical trials to test mAbs against COVID-19 are now enrolling healthy adults in the US, the NIH has announced.
A Phase III trial has been launched to study whether baricitinib, an oral JAK1/JAK2 inhibitor, is effective at combatting COVID-19 in hospitalised patients.
The first patient has been dosed in the Chinese Phase I trial of JS016 in healthy people who do not have a COVID-19 diagnosis.
The enterprise announced the initiation of the LY-CoV555 COVID-19 antibody treatment trial at medical centres across the US.
CYRAMZA in combination with erlotinib was approved as a first-line treatment for metastatic EGFR-mutated non-small cell lung cancer.
The enterprise announced its drug OLUMIANT® (baricitinib) and an investigational antibody will enter clinical trials in US COVID-19 patients later this month.
The International Federation of Pharmaceutical Manufacturers and Associations has announced that the biopharma industry has responding swiftly to the COVID-19 pandemic and will further increase its efforts.
Having become aware of insulin shortages in pharmacies, the company has stated that its products are not backordered and should be available for delivery by wholesalers.
Baricitinib has been granted Breakthrough Therapy as a treatment for alopecia areata, an autoimmune condition with no FDA-approved therapies.
The developers have announced solanezumab failed to show disease-modifying properties against dominantly inherited Alzheimer's disease (DIAD).